The DC vaccine primes tumor‑specific T cells. CD4 TH1/CTL recognize MHC II–restricted neoantigens on MHC II–positive tumor cells and can directly lyse them (perforin/granzyme, Fas–FasL), while also helping CD8 CTLs; the dendritic cells themselves do not kill tumor cells.